13 January 2025 - Ipsen announced today that the US FDA has granted breakthrough therapy designation for IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukaemia, an aggressive blood cancer affecting older adults. 

IPN60340 is an investigational first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer.

Read Ipsen press release